GLP1R and diabetes mellitus: Sodium-glucose co-transporter-2 inhibitors (SGLT2Is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) are antihyperglycemic agents that were approved by the U.S. Food and Drug Administration (FDA) in 2013 and 2012, respectively, for the treatment of non-insulin-dependent diabetes mellitus.